Dive Into Other Topics

Oct 16, 2023

Rare eye diseases can pose burden on patients. Top rare eye diseases are Stargardt Disease, Retinitis Pigmentosa, LHON, Retinoblastoma, LSCD

Oct 13, 2023

On September 29, 2023, FDA approved EXXUA, the ER gepirone hydrochloride tablets by Fabre-Kramer, for major depressive disorder treatment.

Oct 11, 2023

Immunomodulators are reshaping the healthcare market outlook with their diverse benefits and applications, thereby improving health outcomes.

Oct 09, 2023

FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.

Oct 06, 2023

Since scopolamine transdermal patch FDA approval, no other treatments approved in US for nausea and vomiting induced by motion sickness.

Oct 04, 2023

Alzheimer’s Disease represents one of the most pressing challenges in today's healthcare market. As its prevalence continues to soar with the aging global population, the hurdles in its diagnostic and treatment also continue to rise. As per the estimate, globally, about 55 million people are living with dementia in...

Oct 02, 2023

Despite facing significant setbacks, companies such as Eli Lilly, BioVie, and others are developing effective Alzheimer's disease treatments.

Sep 29, 2023

With rise of gene therapy and other innovative therapeutic approaches, we experience profound change in Netherton syndrome treatment space.

Sep 27, 2023

It is not surprising that the healthcare sector is undergoing a significant transition in an era characterized by technological developments and the digitization of almost every aspect of our lives. The development of smart medical devices is a shining illustration of how technology has advanced in healthcare in a ...

Sep 25, 2023

Orchard Therapeutics received FDA acceptance for its BLA for OTL-200, a gene therapy in pipeline for metachromatic leukodystrophy treatment.